Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049349 | 0.94 | SCN9A (0.46) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL5047189 | 0.93 | SCN9A (0.46) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL84881 | 0.92 | SCN9A (0.46) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL12052753 | 0.92 | SCN9A (0.54) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL10082241 | 0.92 | SCN9A (0.56) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL12053944 | 0.92 | SCN9A (0.54) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL850558 | 0.92 | SCN9A (0.45) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL851595 | 0.91 | KCNH2 (0.52) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL5048195 | 0.91 | KCNH2 (0.52) | SCN9ANR1I2KCNH2CYP3A4SCN5A | |
| SCHEMBL84236 | 0.90 | SCN9A (0.44) | SCN9ANR1I2KCNH2CYP3A4SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2118108-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| EP-2121697-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2011-08-31 | — | — | EP | disclosed |
| US-7547690-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | SCN9A 4595/4885NR1I2 189/4885KCNH2 3808/4885 |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, NR1H4 | SCN9A 3775/4885NR1I2 175/4885KCNH2 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.